{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:35:16Z","timestamp":1778618116568,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Addex Pharmaceuticals","award":["RF-2010-2311657"],"award-info":[{"award-number":["RF-2010-2311657"]}]},{"name":"Ministero Salute"},{"DOI":"10.13039\/100001595","name":"Dystonia Medical Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001595","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.neuropharm.2014.06.013","type":"journal-article","created":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T01:14:04Z","timestamp":1403140444000},"page":"440-450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Negative allosteric modulation of mGlu5 receptor rescues striatal D2 dopamine receptor dysfunction in rodent models of DYT1 dystonia"],"prefix":"10.1016","volume":"85","author":[{"given":"G.","family":"Sciamanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Ponterio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tassone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Maltese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Madeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Martella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9842-2372","authenticated-orcid":false,"given":"S.","family":"Poli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Schirinzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bonsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2014.06.013_bib1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3109\/10799893.2010.487492","article-title":"An integrated view on the role of receptor mosaics at perisynaptic level: focus on adenosine A(2A), dopamine D(2), cannabinoid CB(1), and metabotropic glutamate mGlu(5) receptors","volume":"30","author":"Agnati","year":"2010","journal-title":"J.\u00a0Recept. Signal Transduct. Res."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib2","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mds.25475","article-title":"Phenomenology and classification of dystonia: a consensus update","volume":"28","author":"Albanese","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib3","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.tips.2007.02.006","article-title":"The Akt-GSK-3 signaling cascade in the actions of dopamine","volume":"28","author":"Beaulieu","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fnmol.2011.00038","article-title":"Beyond cAMP: the regulation of Akt and GSK3 by Dopamine receptors","volume":"4","author":"Beaulieu","year":"2011","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1046\/j.1471-4159.2002.00815.x","article-title":"Functional and molecular characterization of metabotropic glutamate receptors expressed in rat striatal cholinergic interneurones","volume":"81","author":"Bell","year":"2002","journal-title":"J.\u00a0Neurochem."},{"issue":"Pt 3","key":"10.1016\/j.neuropharm.2014.06.013_bib6","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1113\/jphysiol.2005.098269","article-title":"Excitatory effects of serotonin on rat striatal cholinergic interneurones","volume":"569","author":"Blomeley","year":"2005","journal-title":"J.\u00a0Physiol."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2014.06.013_bib7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.neuropharm.2005.05.012","article-title":"Modulatory action of metabotropic glutamate receptor (mGluR) 5 on mGluR1 function in striatal cholinergic interneurons","volume":"49","author":"Bonsi","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2014.06.013_bib9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrn2337","article-title":"The pathophysiological basis of dystonias","volume":"9","author":"Breakefield","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib10","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/j.1471-4159.2009.06078.x","article-title":"Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells","volume":"109","author":"Cabello","year":"2009","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib11","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1212\/WNL.0b013e3181aa538f","article-title":"Abnormal striatal and thalamic dopamine neurotransmission: genotype-related features of dystonia","volume":"72","author":"Carbon","year":"2009","journal-title":"Neurology"},{"issue":"Pt 13","key":"10.1016\/j.neuropharm.2014.06.013_bib12","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1113\/jphysiol.2013.252197","article-title":"Striatal neurones have a specific ability to respond to phasic dopamine release","volume":"591","author":"Castro","year":"2013","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1042\/AN20120013","article-title":"Dopamine D2 receptor-mediated Akt\/PKB signalling: initiation by the D2S receptor and role in quinpirole-induced behavioural activation","volume":"4","author":"Chen","year":"2012","journal-title":"ASN Neuro"},{"key":"10.1016\/j.neuropharm.2014.06.013_bib14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0014-2999(96)00761-3","article-title":"Spontaneous release of acetylcholine in striatum is preferentially regulated by inhibitory dopamine D2 receptors","volume":"317","author":"DeBoer","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib15","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/npp.2008.129","article-title":"Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease","volume":"34","author":"De Leonibus","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2014.06.013_bib16","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/bph.12164","article-title":"Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease","volume":"169","author":"Doria","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.semcdb.2003.12.018","article-title":"Identification and functional roles of metabotropic glutamate receptor-interacting proteins","volume":"15","author":"Fagni","year":"2004","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib18","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1212\/WNL.33.10.1255","article-title":"High dosage anticholinergic therapy in dystonia","volume":"33","author":"Fahn","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2014.06.013_bib19","doi-asserted-by":"crossref","first-page":"11940","DOI":"10.1073\/pnas.172393799","article-title":"Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function","volume":"99","author":"Ferr\u00e9","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib20","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.2174\/138161208784480108","article-title":"An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors","volume":"14","author":"Ferr\u00e9","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib21","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/ng.2496","article-title":"Mutations in GNAL cause primary torsion dystonia","volume":"45","author":"Fuchs","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib22","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.neuron.2005.11.010","article-title":"Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope","volume":"48","author":"Goodchild","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2014.06.013_bib23","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.tins.2013.09.003","article-title":"New genetic insights highlight \u2018old\u2019 ideas on motor dysfunction in dystonia","volume":"36","author":"Goodchild","year":"2013","journal-title":"Trends Neurosci."},{"issue":"17 Suppl.","key":"10.1016\/j.neuropharm.2014.06.013_bib24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1468-1331.2010.03057.x","article-title":"The role of torsinA in dystonia","volume":"1","author":"Granata","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.nbd.2012.03.024","article-title":"Generation of a novel rodent model for DYT1 dystonia","volume":"47","author":"Grundmann","year":"2012","journal-title":"Neurobiol. Dis."},{"issue":"5","key":"10.1016\/j.neuropharm.2014.06.013_bib26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.pneurobio.2004.09.005","article-title":"Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases","volume":"74","author":"Gubellini","year":"2004","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib27","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S1474-4422(06)70574-9","article-title":"Treatment of dystonia","volume":"5","author":"Jankovic","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib28","series-title":"Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 Modulate Akt and GSK3 \u03b2 Signalling In\u00a0Vivo","author":"Johnson","year":"2013"},{"key":"10.1016\/j.neuropharm.2014.06.013_bib29","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/jpet.110.166629","article-title":"Reduction of l-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"333","author":"Johnston","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib30","doi-asserted-by":"crossref","first-page":"35671","DOI":"10.1074\/jbc.M401923200","article-title":"Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal","volume":"279","author":"Lee","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0306-4522(96)00029-2","article-title":"Expression of the D3 dopamine receptor in peptidergic neurons of the nucleus accumbens: comparison with the D1 and D2 dopamine receptors","volume":"73","author":"Le Moine","year":"1996","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2014.06.013_bib32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.nbd.2007.08.011","article-title":"Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease","volume":"29","author":"Levandis","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib33","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.neuropharm.2010.01.008","article-title":"Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum","volume":"58","author":"Lovinger","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2014.06.013_bib34","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1523\/JNEUROSCI.4360-04.2005","article-title":"The scaffold protein Homer1b\/c links metabotropic glutamate receptor 5 to extracellular signal-regulated protein kinase cascades in neurons","volume":"25","author":"Mao","year":"2005","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2014.01.016","article-title":"Regional specificity of synaptic plasticity deficits in a knock-in mouse model of DYT1 dystonia","author":"Martella","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib36","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.neuropharm.2014.01.014","article-title":"Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys","volume":"79C","author":"Morin","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2014.06.013_bib37","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.neuropharm.2009.12.024","article-title":"Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys","volume":"58","author":"Morin","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2014.06.013_bib38","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.nbd.2010.03.003","article-title":"Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia","volume":"38","author":"Napolitano","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib40","first-page":"163","article-title":"Dysfunction of dopaminergic pathways in dystonia","volume":"94","author":"Perlmutter","year":"2004","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0028-3908(94)00129-G","article-title":"The metabotropic glutamate receptors: structure and functions","volume":"34","author":"Pin","year":"1995","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2014.06.013_bib43","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.nbd.2006.07.006","article-title":"Altered responses to dopaminergic D2 receptor activation and N-type calcium currents in striatal cholinergic interneurons in a mouse model of DYT1 dystonia","volume":"24","author":"Pisani","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib44","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tins.2007.07.008","article-title":"Re-emergence of striatal cholinergic interneurons in movement disorders","volume":"30","author":"Pisani","year":"2007","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib45","series-title":"Antiparkinsonian and Anti-dyskinetic Effects of Dipraglurant (ADX48621), A Novel mGluR5 Negative Allosteric Modulator in Clinical Development","author":"Poli","year":"2011"},{"key":"10.1016\/j.neuropharm.2014.06.013_bib46","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.neuropharm.2013.07.006","article-title":"Powerful inhibitory action of mu opioid receptors (MOR) on cholinergic interneuron excitability in the dorsal striatum","volume":"25","author":"Ponterio","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2014.06.013_bib47","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0893-133X(01)00256-1","article-title":"The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors","volume":"25","author":"Popoli","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2014.06.013_bib48","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/nn1134","article-title":"PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis","volume":"6","author":"Rong","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib49","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.nbd.2010.05.001","article-title":"A\u00a0mGluR5 antagonist under clinical development improves l-DOPA-induced dyskinesia in parkinsonian rats and monkeys","volume":"39","author":"Rylander","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib50","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.neurobiolaging.2007.02.005","article-title":"mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys","volume":"29","author":"Samadi","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2014.06.013_bib51","doi-asserted-by":"crossref","first-page":"e24261","DOI":"10.1371\/journal.pone.0024261","article-title":"Developmental profile of the aberrant dopamine D2 receptor response in striatal cholinergic interneurons in DYT1 dystonia","volume":"6","author":"Sciamanna","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2014.06.013_bib52","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.nbd.2012.04.015","article-title":"Cholinergic dysregulation produced by selective inactivation of the dystonia-associated protein torsinA","volume":"47","author":"Sciamanna","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib53","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.1523\/JNEUROSCI.0855-05.2005","article-title":"Impaired motor learning in mice expressing torsinA with the DYT1 dystonia mutation","volume":"25","author":"Sharma","year":"2005","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib54","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/B978-0-12-385952-5.00010-5","article-title":"Allosteric modulation of metabotropic glutamate receptors","volume":"62","author":"Sheffler","year":"2011","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib55","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/mds.25561","article-title":"AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study","volume":"28","author":"Stocchi","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib56","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0006-8993(97)01141-4","article-title":"Localization of mGluR1a-like immunoreactivity and mGluR5-like immunoreactivity in identified populations of striatal neurons","volume":"780","author":"Tallaksen-Greene","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib57","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.80.7_supplement.S23.004","article-title":"Safety, tolerability and anti-dyskinetic efficacy of dipraglurant, a novel mGluR5 negative allosteric modulator (NAM) in Parkinson's disease (PD) patients with levodopa-induced dyskinesia (LID)","volume":"80","author":"Tison","year":"2013","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neuropharm.2014.06.013_bib58","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.expneurol.2008.04.020","article-title":"Commentary: dopaminergic dysfunction in DYT1 dystonia","volume":"212","author":"Wichmann","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib59","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1152\/jn.1997.77.2.1003","article-title":"D2 dopamine receptors reduce N-type Ca2+ currents in rat neostriatal cholinergic interneurons through a membrane-delimited, protein-kinase-C-insensitive pathway","volume":"77","author":"Yan","year":"1997","journal-title":"J.\u00a0Neurophysiol."},{"key":"10.1016\/j.neuropharm.2014.06.013_bib60","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/neu.10150","article-title":"Cholinergic interneuron characteristics and nicotinic properties in the striatum","volume":"53","author":"Zhou","year":"2002","journal-title":"J.\u00a0Neurobiol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814002354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814002354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T21:36:15Z","timestamp":1716845775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390814002354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":57,"alternative-id":["S0028390814002354"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.06.013","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Negative allosteric modulation of mGlu5 receptor rescues striatal D2 dopamine receptor dysfunction in rodent models of DYT1 dystonia","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}